User profiles for Sharon L. Walmsley
 | Sharon WalmsleyUniversity Health Network Verified email at uhn.ca Cited by 27724 |
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
…, AR Rachlis, DB Rose, HA Dwosh, SL Walmsley… - Jama, 2003 - jamanetwork.com
ContextSevere acute respiratory syndrome (SARS) is an emerging infectious disease that
first manifested in humans in China in November 2002 and has subsequently spread …
first manifested in humans in China in November 2002 and has subsequently spread …
[HTML][HTML] Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection
SL Walmsley, A Antela, N Clumeck… - … England Journal of …, 2013 - Mass Medical Soc
Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …
recently approved in the United States for the treatment of human immunodeficiency virus …
[HTML][HTML] Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome
…, G Tomlinson, T Mazzulli, SL Walmsley… - Archives of internal …, 2007 - jamanetwork.com
Background Severe Acute Respiratory Syndrome (SARS) became a global epidemic in
2003. Comprehensive information on 1-year outcomes and health care utilization is lacking. …
2003. Comprehensive information on 1-year outcomes and health care utilization is lacking. …
Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects
…, J Chau, C Tam, CM Kovacs, IE Salit, SL Walmsley - Aids, 1998 - journals.lww.com
Objectives: The HIV-infected population is known to be oxidatively stressed and deficient in
antioxidant micronutrients. Since in vitro replication of HIV is increased with oxidative stress, …
antioxidant micronutrients. Since in vitro replication of HIV is increased with oxidative stress, …
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients …
CB Hicks, P Cahn, DA Cooper, SL Walmsley… - The Lancet, 2006 - thelancet.com
Background Treatment options for HIV-1 infected individuals who have received extensive
previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-…
previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-…
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
…, VIKING Study Group, SL Walmsley… - The Journal of …, 2013 - academic.oup.com
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1)
integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in …
integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in …
[HTML][HTML] A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus …
…, P Phillips, I Salit, SL Walmsley… - … England Journal of …, 1996 - Mass Medical Soc
Background Bacteremia with the Mycobacterium avium complex is common in patients with
the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this …
the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this …
[HTML][HTML] Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study
…, SS Mohammed, DS Su, ED Ralph, SL Walmsley… - PloS one, 2009 - journals.plos.org
Background Improvements in life expectancy and quality of life for HIV-positive women
coupled with reduced vertical transmission will likely lead numerous HIV-positive women to …
coupled with reduced vertical transmission will likely lead numerous HIV-positive women to …
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3 …
…, S Hartl, R Zangerle, F Smaill, SL Walmsley… - The lancet HIV, 2018 - thelancet.com
Background Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …